Objective: We describe the neurologic, neuroradiologic, and ophthalmologic phenotype of 1 Swedish and 1 Finnish family with autosomal dominant ataxia-pancytopenia (ATXPC) syndrome and SAMD9L mutations.
ATXPC has so far been described in 5 families, [1] [2] [3] [4] [5] including the Swedish family (F1) and Finnish family (F2) reported here. Recently, missense mutations in sterile alpha motif domain-containing protein 9-like (SAMD9L) have been identified as the cause of ATXPC in 4 of these families. 1, 5 Following the genetic discovery, we studied the neurologic phenotype in F1 and F2.
METHODS Affected and unaffected family members of both families were examined by a neurologist. A structured interview and examination were performed including all clinical features previously described in ATXPC families, [2] [3] [4] [5] and the Scale for the assessment and rating of ataxia. 6 Neuroradiologic images were compiled. Eye movement examination was filmed and reviewed by a neuro-otologist. Medical records were obtained whenever possible. Results of previous blood cell counts were reviewed, and new blood samples were taken. DNA was extracted using standard methods from the peripheral blood or buccal swabs. 1 Some of the genetic analyses and clinical (hematologic) information have previously been published. 1 For this study, F1 was expanded; newly included family members were tested with a custom droplet digital PCR TaqMan genotyping assay for the SAMD9L c.2956C.T mutation (primers available on request). Two patients underwent detailed ophthalmologic examination, including optical coherence tomography, full-field electroretinography, and multifocal electroretinography (mfERG; appendix e-1 at Neurology.org/ng).
Standard protocol approvals, registrations, and patient consents. This study was approved by the responsible regional ethical standards committees. Informed consent was obtained from all participants.
RESULTS Data were compiled from 21 members of F1 and 6 members of F2. The pedigrees, individual neurologic phenotype, and SAMD9L genotype are shown in figure 1 and table, and patient descriptions in appendix e-1 and videos 1-3. DNA was obtained from 18 members of F1 and 6 members from F2. All mutation carriers who were examined within this study showed neurologic signs except the 4-year-old mutation carrier, F1: V-2, who had no obvious neurologic signs or symptoms according to her parents. Individual F1: IV-5 declined participation. Thirteen family members were examined who were subsequently shown not to carry SAMD9L mutations; these did not have neurologic signs or symptoms.
F1: III-4 presented at our neurology clinic at age 53 years because of mild balance problems and a positive family history (figure 1). No SAMD9L mutation c.3587G.C, p.Cys1196Ser 54
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Neurology: Genetics was identified in DNA from the peripheral blood, but nonhematopoietic cells from buccal swabs carried heterozygous SAMD9L c.2956C.T (p.Arg986Cys) mutations. 1 His mother and maternal grandmother had similar symptoms that had progressed slowly. None of the other members of this family sought medical attention because of neurologic or ophthalmologic symptoms, but on direct inquiry, all patients examined reported mild balance impairment, for example during sports, and problems with gaze fixation.
F2: II-4 was referred to a pediatric neurologist at the age of 7 years after a single seizure during sleep. He had balance impairment, nystagmus, dysmetria, brisk Achilles tendon reflexes and muscle stiffness in the lower limbs. Symptoms had developed during the last months. His mother, F2: I-2, was investigated at the same time at the age of 32 years by a neurologist for memory problems, nystagmus, lower limb weakness, and balance problems. His brother, F2: II-1, had mild neurologic symptoms. The neurologic phenotype within the family ranged from nearly normal to marked disability. As described previously, a heterozygous SAMD9L c.2672T.C (p.Ile891Thr) mutation was identified in DNA from the peripheral blood from all three affected individuals. 1 The hematologic disorders of the family members have been described. 1 Transient or permanent cytopenia was detected in 8 of 12 patients. Two children underwent hematopoietic stem cell transplantation (HSCT) because of myelodysplastic syndrome at 2 and 4.5 years. One of these patients (F1:V-1) had no neurologic symptoms prior to HSCT, but 3 months later, ataxic gait and nystagmus were noted. Similar treatment did not lead to neurologic worsening in F2: II-4, in whom follow-up MRI showed decreasing white matter abnormalities (figure 2B, appendix e-1).
F1: III-4 had noticed difficulties with gaze fixation during several years, and sometimes experienced difficulty reading or tendency to manual clumsiness, for example, when dining. Also, he sometimes found it cumbersome to see in conditions with low ambient light, such as during dawn, dusk, or in foggy weather conditions. Examination by mfERG, which reflects cone function in the posterior pole, demonstrated a reduction of paramacular cone function ( figure  2C ). In F1: IV-4, there was similar but milder paracentral retinal dysfunction. Other patients from both families reported very similar symptoms.
DISCUSSION The neurologic phenotype of ATXPC with SAMD9L mutations is characterized by nystagmus and slowly progressive balance impairment. These signs were found in almost all SAMD9L mutation carriers examined in this study (table) . The Table   Continued ID: ref Testing of blood-DNA from this individual did not reveal a mutation, but the mutation was identified in DNA from nonhematopoietic cells from buccal swabs, because of mosaicism in blood cells. neuro-otological findings indicate midline cerebellar dysfunction. Balance impairment was clearly visible on examination, 6 but it was mild or very mild in some patients with only difficulty with tandem walking or standing in a tandem position. Additional signs include mild pyramidal signs, strabismus, and decreased vibration sense. Neuroimaging revealed marked cerebellar atrophy in all 8 patients and periventricular white matter changes in 6 of 8 ( figure 2) . Attention deficit hyperactivity disorder or cognitive problems were noticed in 4 patients, but it remains uncertain if these are related to the disorder.
Ophthalmological symptoms or signs have not previously been described for ATXPC with SAMD9L mutations. Adult patients from both families reported reading and focusing difficulties. mfERG showed intact function in the most central area but marked paracentral (cone) dysfunction, which correlates with these visual symptoms. Similar ophthalmologic findings have been reported, for example, in patients with SCA7. 7 We suggest that some of the "atactic" signs in the upper extremities noted in patients with SAMD9L mutations may in fact be caused by a decrease in visual control of hand movements, rather than cerebellar ataxia.
In our as well as all previously reported families, all carriers of pathogenic SAMD9L mutations developed neurologic signs. Expressivity was variable from individuals experiencing marked balance impairment to those who only noticed mild problems with balance or gaze fixation. Careful neurologic examination, however, revealed clearly abnormal signs in all carriers with complete penetrance. The hematologic disorders in members of both families have previously been described in detail. 1 In these and the other families, there was pancytopenia with a risk of severe hemorrhages or infections on the one hand, and myelodysplastic syndrome on the other hand, but these hematologic abnormalities were not noticed in all mutation carriers (table) .
One of SAMD9L's roles is that of a tumor suppressor or inhibitor of uncontrolled cell division. 8 There is strong evidence that the disease-causing mutations exert a gain-of-function mechanism, resulting in more pronounced inhibition of cell division, which in blood cell lineages causes pancytopenia and genetic pressure to eliminate the mutant copy of the SAMD9L gene.
1 Also in ataxia-telangiectasia, cerebellar degeneration co-occurs with immunologic deficiencies, lymphopenia, and increased risk of lymphoid malignancies. 9 While dysfunction of DNA repair caused by mutations in ATM underlies some of the features of ataxia-telangiectasia, the cause of cerebellar degeneration in ataxia-telangiectasia remains difficult to explain. Perhaps similar to SAMD9L, ATM also influences cell-cycle signaling and cellular homeostasis pathways and interacts with another tumor suppressor, p53, in the cell-cycle control system. 10 Cerebellar Purkinje cells and retinal cells might be particularly vulnerable to the effect of SAMD9L mutations.
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